Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 42.9% during the first quarter, Holdings Channel reports. The fund owned 3,030 shares of the company’s stock after buying an additional 910 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC’s holdings in Neurocrine Biosciences were worth $266,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. SG Americas Securities LLC lifted its stake in Neurocrine Biosciences by 6.8% during the first quarter. SG Americas Securities LLC now owns 2,106 shares of the company’s stock worth $186,000 after purchasing an additional 135 shares in the last quarter. Sumitomo Life Insurance Co. increased its position in shares of Neurocrine Biosciences by 1.8% during the fourth quarter. Sumitomo Life Insurance Co. now owns 9,939 shares of the company’s stock worth $710,000 after acquiring an additional 180 shares during the period. JGP Global Gestao de Recursos Ltda. increased its position in shares of Neurocrine Biosciences by 9.4% during the first quarter. JGP Global Gestao de Recursos Ltda. now owns 3,278 shares of the company’s stock worth $289,000 after acquiring an additional 281 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Neurocrine Biosciences by 6.4% during the first quarter. Nisa Investment Advisors LLC now owns 5,965 shares of the company’s stock worth $526,000 after acquiring an additional 358 shares during the period. Finally, Steinberg Global Asset Management increased its position in shares of Neurocrine Biosciences by 2.7% during the first quarter. Steinberg Global Asset Management now owns 15,923 shares of the company’s stock worth $1,403,000 after acquiring an additional 412 shares during the period.

In related news, insider Haig P. Bozigian sold 66,667 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $80.13, for a total value of $5,342,026.71. Following the completion of the sale, the insider now owns 164,415 shares in the company, valued at $13,174,573.95. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Haig P. Bozigian sold 1,300 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $80.03, for a total transaction of $104,039.00. Following the completion of the sale, the insider now owns 143,276 shares of the company’s stock, valued at approximately $11,466,378.28. The disclosure for this sale can be found here. In the last 90 days, insiders sold 102,514 shares of company stock valued at $8,054,710. 4.30% of the stock is owned by insiders.

Shares of NBIX opened at $78.75 on Friday. Neurocrine Biosciences, Inc. has a fifty-two week low of $64.72 and a fifty-two week high of $126.98. The stock has a market cap of $7.28 billion, a PE ratio of 357.95 and a beta of 1.73. The company has a debt-to-equity ratio of 0.96, a current ratio of 8.79 and a quick ratio of 8.61.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, April 29th. The company reported ($1.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.07). The firm had revenue of $138.40 million during the quarter, compared to analyst estimates of $136.77 million. Neurocrine Biosciences had a negative net margin of 7.56% and a negative return on equity of 9.14%. Neurocrine Biosciences’s revenue for the quarter was up 94.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.47) EPS. On average, sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post -0.24 EPS for the current year.

Several equities analysts recently commented on NBIX shares. Needham & Company LLC lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Oppenheimer set a $105.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Tuesday, January 29th. Cantor Fitzgerald reiterated a “buy” rating and set a $121.00 target price on shares of Neurocrine Biosciences in a research note on Tuesday, January 29th. HC Wainwright reiterated a “buy” rating on shares of Neurocrine Biosciences in a research note on Wednesday, January 30th. Finally, Bank of America decreased their target price on shares of Neurocrine Biosciences from $124.00 to $117.00 and set a “buy” rating for the company in a research note on Wednesday, February 6th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Neurocrine Biosciences currently has a consensus rating of “Buy” and a consensus price target of $102.95.

COPYRIGHT VIOLATION NOTICE: “Neurocrine Biosciences, Inc. (NBIX) Position Lifted by Nelson Van Denburg & Campbell Wealth Management Group LLC” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://theolympiareport.com/2019/05/24/neurocrine-biosciences-inc-nbix-position-lifted-by-nelson-van-denburg-campbell-wealth-management-group-llc.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Further Reading: Insider Trading

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.